Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.98B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 4.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| TVTX | XLY | |
|---|---|---|
Market Cap | $4.88B | $21.98B |
Volume | 1,668,577 | 5,684,050 |
Sector | Health | — |
52-Week High | $67.52 | $124.52 |
52-Week Low | $26.79 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLY trades at $112.36 with minimal daily movement (+0.07%), showing technical indecision with a bullish overall signal but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% while consumer staples gained 6.6%. Analyst consensus remains unanimously bullish with a 100% buy rating, though recent news highlights persistent underperformance concerns and consumer spending shifts toward value.
The outlook remains mixed with technical indicators suggesting potential resistance near $113 while fundamental exposure to consumer discretionary spending faces inflation pressures. Key risks include continued market underperformance and consumer sensitivity to economic conditions, though potential catalysts exist from holiday retail growth projections and cyclical sector opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
